|
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene(R) I.V. Compared To Labetalol In P
EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene I.V.(nicardipine hydrochloride) is significantly more effective than intravenous...
|
|
|
Medical News: Interim Study Data Indicate Improved Blood Pressure Management With Cardene(R) I.V. Compared To Labetalol In Patients With Acute Stroke
EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene I.V.(nicardipine hydrochloride) is significantly more effective than intravenous...
|
|
|
Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients
EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data demonstrate that Cardene I.V.(nicardipine hydrochloride) is significantly more effective than intravenous...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene(R) I.V. Compared to Labetalol in P
BEDMINSTER, N.J.--(HSMN NewsFeed)--EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene(R) I.V.(nicardipine hydrochloride) is significantly more...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V. Compared to Labetalol in Patients with Acute Stoke
EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene I.V.(nicardipine hydrochloride) is significantly more effective than intravenous...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V. Compared to Labetalol in Pa
EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene I.V.(nicardipine hydrochloride) is significantly more effective than intravenous...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V. Compared to Labetalol in Patients with
BEDMINSTER, N.J.- (BUSINESS WIRE) - EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene I.V. (nicardipine hydrochloride) is...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V. Compared to Labetalol in Patients with Acute Stoke
Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V.Compared to Labetalol in Patients with Acute Stoke BEDMINSTER, N.J.--(BUSINESS WIRE)--EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V. Compared to Labetalol in Patients with Acute Stoke
EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene I.V.(nicardipine hydrochloride) is significantly more effective than intravenous...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V. Compared to Labetalol in Patients with Acute Stoke
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); BEDMINSTER, N.J.- (Business Wire) EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that ...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene(R) I.V. Compared to
BusinessWire - EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data(1) demonstrate that Cardene(R) I.V.(nicardipine hydrochloride) is significantly more effective than...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene(R) I.V. Compared to Labetalol in P
EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data(1) demonstrate that Cardene(R) I.V.(nicardipine hydrochloride) is significantly more effective than intravenous...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene(R) I.V. Compared to Labetalol in Patients with Acute Stoke
BEDMINSTER, N.J.--(BUSINESS WIRE)-- EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene(R) I.V.(nicardipine hydrochloride) is significantly more...
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V. Compared to Labetalol in Patients with Acute Stoke
_ Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V.Compared to Labetalol in Patients with Acute Stoke.
|
|
|
Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V. Compared to Labetalol in Pa
_ Interim Study Data Indicate Improved Blood Pressure Management With Cardene I.V.Compared to Labetalol in Pa.
|
|
|
Blood pressure drugs tied to lower Parkinson's risk
-0400 (Reuters Health) By Amy Norton NEW YORK (Reuters Health) - People who use a particular class of blood pressure drug may have a decreased risk of developing Parkinson's disease, a new study suggests.The medications in question are a type of calcium...
|
|
|
Wockhardt launches anti-hypertensive drug Nicardipine injections in USA
Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing the 25mg/10 ml injection of Nicardipine HCl, which is used for short-term management of hypertension or...
|
